Japonicone A suppresses growth of Burkitt lymphoma cells through its effect on NF-κB

Clinical Cancer Research

Volumn 19, Issue 11, 2013, Pages 2917-2928

  Li, Xiaoguang ^a   Yang, Xinying ^a   Liu, Yanling ^a   Gong, Nuoxi ^a   Yao, Wenbo ^a   Chen, Peizhan ^a   Qin, Jiangjiang ^c,e   Jin, Huizi ^c   Li, Jingquan ^a,d   Chu, Ruiai ^a,d   Shan, Lei ^b   Zhang, Ruiwen ^e   Zhang, Weidong ^b,c   Wang, Hui ^a,d  

^a Chinese Academy of Sciences   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d BEIJING HOSPITAL   (China)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JAPONICONE A; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY TEST; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; ENZYME INACTIVATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REPORTER GENE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BURKITT LYMPHOMA; CELL CYCLE; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; MAP KINASE KINASE KINASES; MICE; NF-KAPPA B; PROTEIN TRANSPORT; SESQUITERPENES, EUDESMANE; SESQUITERPENES, GUAIANE; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878977786     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3258     Document Type: Article

References (50)

1. Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, et al. Burkitt's lymphoma. Lancet 2012;379:1234-44.
2. Ferry JA. Burkitt lymphoma: clinicopathologic features and differential diagnosis. Oncologist 2006;11:375-83.
3. Bornkamm GW. Epstein-Barr virus and the pathogenesis of Burkitt's lymphoma: more questions than answers. Int J Cancer 2009;124:1745-55.
4. Mbulaiteye SM, Biggar RJ, Bhatia K, Linet MS, Devesa SS. Sporadic childhood Burkitt lymphoma incidence in the United States during 1992-2005. Pediatr Blood Cancer 2009;53:366-70
5. Allday MJ. How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma? Sem Cancer Biol 2009;19:366-76.
6. Dang CV, O'Donnell KA, Juopperi T. The great MYC escape in tumorigenesis. Cancer Cell 2005;8:177-8. (Pubitemid 41317588)
7. Perkins AS, Friedberg JW. Burkitt lymphoma in adults. Hematol Am Soc Hematol Educ Program 2008:341-8
8. Yustein JT, Dang CV. Biology and treatment of Burkitt's lymphoma. Curr Opin Hematol 2007;14:375-81. (Pubitemid 46842812)
9. Gerecitano J, Straus DJ. Treatment of Burkitt lymphoma in adults. Expert Rev Anticancer Ther 2006;6:373-81. (Pubitemid 44192919)
10. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002;2:725-34.
11. Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be, or not to be: NF-kappaB is the answer - role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003;22:8961-82. (Pubitemid 38121698)
12. Perkins ND. The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer 2012;12:121-32.
13. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007;109:2700-7. (Pubitemid 46482061)
14. Chaudhary PM, Jasmin A, Eby MT, Hood L. Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins. Oncogene 1999 18:5738-46. (Pubitemid 29507427)
15. Tafuku S, Matsuda T, Kawakami H, Tomita M, Yagita H, Mori N. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma. Eur J Haematol 2006;76:64-74.
16. Schlee M, Holzel M, Bernard S, Mailhammer R, Schuhmacher M, Reschke J, et al. C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma. Int J Cancer 2007;120:1387-95. (Pubitemid 46355371)
17. Kanda K, Hu HM, Zhang L, Grandchamps J, Boxer LM. NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer. J Biol Chem 2000;275:32338-46.
18. Clardy J, Walsh C. Lessons from natural molecules. Nature 2004;432:829-37. (Pubitemid 40037138)
19. Mishra BB, Tiwari VK. Natural products: an evolving role in future drug discovery. Eur J Med Chem 2011;46:4769-807.
20. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005;4:206-20. (Pubitemid 40372555)
21. Ji HF, Li XJ, Zhang HY. Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep 2009;10:194-200.
22. Qin JJ, Jin HZ, Zhu JX, Fu JJ, Hu XJ, Liu XH, et al. Japonicones E-L, dimeric sesquiterpene lactones from Inula japonica Thunb. Planta Med 2010;76:278-83.
23. Jin HZ, Lee D, Lee JH, Lee K, Hong Y-S, Choung D-H, et al. New sesquiterpene dimers from Inula britannica inhibit NF-kappaB activation and NO and TNF-alpha production in LPS-stimulated RAW264.7 cells. Planta Medica 2006;72:40-5. (Pubitemid 43241590)
24. Qin JJ, Jin HZ, Fu JJ, Hu XJ, Wang Y, Yan SK, et al. Japonicones A-D, bioactive dimeric sesquiterpenes from Inula japonica Thunb. Bioorg Med Chem Lett 2009;19:710-3
25. Hou J, Wang D, Zhang R, Wang H. Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 2008;14:5519-30.
26. Yang X, Du L, Tang X, Jung SY, Zheng B, Soh BY, et al. Brevicompanine E reduces lipopolysaccharide-induced production of proinflammatory cytokines and enzymes in microglia by inhibiting activation of activator protein-1 and nuclear factor-kappaB. J Neuroimmunol 2009;216:32-8.
27. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;44:431-6. (Pubitemid 44050137)
28. Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T, et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 2005;6:1087-95. (Pubitemid 41541786)
29. Chen ZJ, Bhoj V, Seth RB. Ubiquitin, TAK1 and IKK: is there a connection? Cell Death Differ 2006;13:687-92.
30. Shim J-H, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 2005;19:2668-81. (Pubitemid 41627934)
31. Buglio D, Palakurthi S, Byth K, Vega F, Toader D, Saeh J, et al. Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood 2012;120:347-55.
32. Shibuya H, Yamaguchi K, Shirakabe K, Tonegawa A, Gotoh Y, Ueno N, et al. TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 1996;272:1179-82.
33. Basseres DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006;25:6817-30. (Pubitemid 44657854)
34. Courtois G, Gilmore TD. Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 2006;25:6831-43. (Pubitemid 44657855)
35. God JM, Haque A. Burkitt lymphoma: pathogenesis and immune evasion. J Oncol 2010;2010:516047.
36. Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2007;6:37-50. (Pubitemid 46206667)
37. Srivastava SK, Singh SV. Cell cycle arrest, apoptosis induction and inhibition of nuclear factor kappa B activation in anti-proliferative activity of benzyl isothiocyanate against human pancreatic cancer cells. Carcinogenesis 2004;25:1701-9. (Pubitemid 39214313)
38. 2-M cell cycle progression by the ERK5-NFkappaB signaling pathway. J Cell Biol 2007;177:253-64.
39. Bauerle KT, Schweppe RE, Haugen BR. Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Mol Cancer 2010;9:117.
40. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science 1989;246:629-34. (Pubitemid 19283354)
41. Luo J-L, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest 2005;115:2625-32. (Pubitemid 41434385)
42. Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, et al. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011;471:523-6.
43. Turan T, Aykan B, Koc S, Boran N, Tulunay G, Karacay O, et al. Analysis of metastatic ovarian tumors from extragenital primary sites. Tumori 2006;92:491-5. (Pubitemid 46166301)
44. Yazigi R, Sandstad J. Ovarian involvement in extragenital cancer. Gynecol Oncol 1989;34:84-7. (Pubitemid 19187969)
45. Yamane T, Kirimoto K, Fujita M, Naka T, Tsubakio T, Ishikawa K, et al. Ovarian involvement as an initial manifestation of malignant lymphoma. Jpn J Clin Oncol 1989;19:163-6.
46. Chen T, Xu Y, Guo H, Liu Y, Hu P, Yang X, et al. Experimental therapy of ovarian cancer with synthetic makaluvamine analog: in vitro and in vivo anticancer activity and molecular mechanisms of action. PLoS ONE 2011;6:e20729.
47. Wang W, Wang H, Rayburn ER, Zhao Y, Hill DL, Zhang R. 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action. Br J Cancer 2008;98:792-802. (Pubitemid 351272613)
48. Chen T, Li M, Zhang R, Wang H. Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med 2009;13:1358-70.
49. Siedle B, Garcia-Pineres AJ, Murillo R, Schulte-Monting J, Castro V, Rungeler P, et al. Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem 2004;47:6042-54. (Pubitemid 39507346)
50. Lim K-H, Yang Y, Staudt LM. Pathogenetic importance and therapeutic implications of NF-kappaB in lymphoid malignancies. Immunol Rev 2012;246:359-78. Foundation Foundation Foundation Foundation Foundation